Clinical Trial Update: A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial is evaluating the addition of selinexor to the Rituximab-Gemcitabine-Dexamethasone-Platinum regimen for relapsed/refractory diffuse l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• CISPLATIN (cisplatin)
• DEXAMETHASONE (Dexamethasone)
• Gemcitabine (Gemcitabine)
• Rituximab (rituximab)
• Selinexor (selinexor)

Snippet

Sponsor: Karyopharm Therapeutics Inc | Conditions: Relapsed/Refractory Diffuse Large B-cell Lymphoma | Phase 2, Phase 3 | Status: RECRUITING